Pair page
Thymagen with Vilon
Mechanism-tag overlap and published literature for Thymagen and Vilon, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
khavinson-thymic-immune-bioregulator
khavinson-dipeptide-immunomodulator
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Thymagen and Vilon have published these mechanism-level observations. Not a co-administration recommendation.
Fellow thymic dipeptide (Lys-Glu; KE) from the Khavinson system. Thymagen (EW) and Vilon (KE) are often paired in practice as complementary thymic-axis bioregulators with proposed distinct peptide-DNA interactions.
Quick facts
Thymagen
Vilon
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2021 | Thymagen | Khavinson VK, Linkova NS, Kukanova EO, Bolshakova AV, Gainullina AN. Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19. Stem Cell Rev Rep. 2021. PMID: 33575961. PMID 33575961 | human study |
| 1996 | Thymagen | Zhuk EA, Galenok VA. Timogen v lechenii sakharnogo diabeta I tipa [Thymogen in the treatment of type-1 diabetes mellitus]. Ter Arkh. 1996;68(10):12-14. Russian. PMID: 9026934. PMID 9026934 | human study |
| 2001 | Thymagen | Anisimov VN, Khavinson VKh, Morozov VG. Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats. Biogerontology. 2001;2(1):47-55. PMID: 11707921. (Chronic rodent dosing — longevity and anti-carcinogenesis signal.) PMID 11707921 | preclinical, in vivo |
| 1989 | Thymagen | Bespalov VG, Troian DN, Petrov AS, Morozov VG, Khavinson VKh. Ingibiruiushchii effekt timogena na razvitie opukholei pishchevoda i predzheludka, indutsirovannykh etilovym efirom N-nitrozosarkozina u krys [Inhibiting effect of thymogen on the development of tumors of the esophagu… PMID 2759010 | preclinical, in vivo |
| 2022 | Thymagen | Khavinson VK, Linkova NS, Kukanova EO, Bolshakova AV, Gainullina AN, Tendler SM, Morozov VG, Tarnovskaya SI, Vanyushin BF, Shataeva LK, Bakaeva ZV. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. Int J Mol Sci. 202… | preclinical, in vitro |
| 2021 | Thymagen | Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of cell differentiation, gene expression, and protein synthesis. Bull Exp Biol Med. 2021;170(5):707-711. | mechanism / discovery |
| 2003 | Thymagen | Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID: 12937678. (Methodological style of Khavinson mechanistic papers.) PMID 12937678 | mechanism / discovery |
| 1997 | Thymagen | Kozlov VA, Khavinson VKh. Natural and synthetic thymic peptides as therapeutics for immune dysfunction. Int Immunopharmacol. 1997;19(9-10):501-505. doi:10.1016/S0192-0561(97)00058-1. (Foundational Western-indexed characterization of Thymalin and Thymogen.) | mechanism / discovery |
| 1997 | Thymagen | Morozov VG, Khavinson VKh. Natural and synthetic thymic peptides: isolation, structure, and biological activity. Int J Immunopharmacol. 1997;19(9-10):501-505. (Original characterization.) | mechanism / discovery |
| 2002 | Thymagen | Khavinson VK. Peptides and Ageing. Neuroendocrinol Lett. 2002;23 Suppl 3:11-144. PMID: 12374906. (Foundational review of the Khavinson peptide bioregulator program.) PMID 12374906 | review |
| 2025 | Thymagen | FDA. Bulk Drug Substances Nominated for Use in Compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. FDA.gov. Updated 2025–2026 (Thymagen / EW dipeptide / Thymogen not listed). | regulatory / registry |
| 2011 | Thymagen | Khavinson VK, Linkova NS, Trofimov AV, Polyakova VO, Sevostyanova NN, Kvetnoy IM. Morphofunctional fundamentals for peptide regulation of aging. Biogerontology. 2011;12(2):95-106. (Supporting mechanistic framework.) | bioregulator literature |
| 2021 | Vilon | Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: a systematic review. Molecules. 2021;26(22):7053. PMID: 34834146. PMID 34834146 | systematic review |
| 2016 | Vilon | Linkova NS, Drobintseva AO, Orlova OA, Kuznetsova EP, Polyakova VO, Kvetnoy IM, Khavinson VKh. Peptide regulation of skin fibroblast functions during their aging in vitro. Bull Exp Biol Med. 2016;161(1):175-178. PMID: 27265131. PMID 27265131 | preclinical, in vitro |
| 2016 | Vilon | Khavinson VKh, Linkova NS, Tarnovskaya SI. Short peptides regulate gene expression. Bull Exp Biol Med. 2016;162(2):288-292. PMID: 27905024. PMID 27905024 | mechanism / discovery |
| 2014 | Vilon | Khavinson VKh, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, Ashapkin VV, Polyakova VO. Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014;192(5):781-791. PMID: 24920421. PMID 24920421 | mechanism / discovery |
| 2003 | Vilon | Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID: 12937682. PMID 12937682 | mechanism / discovery |
| 2025 | Vilon | World Anti-Doping Agency. 2025 WADA Prohibited List. WADA, 2025. | regulatory / registry |
| 2013 | Vilon | Khavinson VKh, Kuznik BI, Ryzhak GA. Peptide bioregulators: a new class of geroprotectors. Adv Gerontol. 2013;3(2):83-93. | bioregulator literature |
| 2012 | Vilon | Kuznik BI, Khavinson VKh, Linkova NS. Heat shock proteins, peptide bioregulators, and aging. Adv Gerontol. 2012;25(3):371-380. | bioregulator literature |
| 2010 | Vilon | Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 19609712. PMID 19609712 | bioregulator literature |
| 2005 | Vilon | Khavinson VKh, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Karger, Basel, 2005. | bioregulator literature |
| 2003 | Vilon | Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PMID: 14523363. PMID 14523363 | bioregulator literature |
| 2002 | Vilon | Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. PMID: 12373186. PMID 12373186 | bioregulator literature |
Related pair pages
More research context
Frequently asked
Have Thymagen and Vilon been studied together?
Researchers have published mechanistic-level co-administration discussion of Thymagen and Vilon. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Thymagen and Vilon share?
Thymagen and Vilon do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Thymagen and Vilon?
Thymagen: Not approved. Vilon: Not approved. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Thymagen and Vilon?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Thymagen profile and the Vilon profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026